MARC Record from marc_columbia

LEADER: 05150pam a22003734a 4500
001 5358378
005 20050927120759.0
008 041115s2005 njua af 001 0 eng
010 $a 2004027077
015 $aGBA531022$2bnb
016 7 $a013174678$2Uk
020 $a0471213845 (cloth)
035 $a(OCoLC)ocm57001932
035 $a(NNC)5358378
040 $aDLC$cDLC$dYDX$dUKM$dBAKER$dNNC-M$dOrLoB-B
042 $apcc
049 $aZCHA
050 00 $aRM301.25$b.D784 2005
082 00 $a615/.19$222
245 00 $aDrug discovery handbook /$cedited by Shayne Cox Gad.
260 $aHoboken, N.J. :$bWiley-Interscience/J. Wiley,$cc2005.
300 $axix, 1471 p. :$bill. ;$c25 cm.
504 $aIncludes bibliographical references and index.
505 00 $tIntroduction : drug discovery in the 21[superscript st] century -- $g1.$tNatural products /$rCharles B. Spainhour -- $g2.$tCancer cell proteomics using molecular aptamers /$rWeihong Tan, Zehui Cao, Dihua Shangguan, Ying Li, Zhiwen Tang, Prabodhika Mallikratchy and Hui Chen -- $g3.$tMolecular similarity methods and QSAR models as tools for virtual screening /$rJurgen Bajorath -- $g4.$tSystems biology : applications in drug discovery /$rSean Ekins, Andrej Bugrim, Yuri Nikolsky and Tatiana Nikolskaya -- $g5.$tHigh-throughput flow cytometry /$rLarry A. Sklar, Peter C. Simons, Anna Waller, Sean M. Biggs, Susan M. Young, Marius Olah, Cristian Bologa, Tudor J. Oprea, Eric R. Prossnitz and Bruce S. Edwards -- $g6.$tCombining NMR spectral information with associated structural features to form computationally nonintensive, rugged, and objective models of biological activity /$rRichard D. Beger, Dan A. Buzatu and Jon G. Wilkes -- $g7.$tUsing Microsoft Excel as a laboratory data management tool /$rA. Erik Rubin, Mark F. Russo and William Neil -- $g8.$tAge of regulation /$rSandy Weinberg and Gerald J. Whartenby -- $g9.$tSimultaneous screening of multiple cell lines using the CellCard system /$rOren E. Beske -- $g10.$tProtein X-ray crystallography in drug discovery /$rPeter Nollert, Michael D. Feese, Bart L. Staker and Hidong Kim -- $g11.$tBiological and chemistry assays available during drug discovery and developability assessment /$rDuane B. Lakings -- $g12.$tStrategies and methods in monitoring and targeting protein-protein interactions /$rArianna Loregian and Giorgio Palu -- $g13.$tHigh-throughput screening : evolution of technology and methods /$rMartyn N. Banks, Angela M. Cacace, Jonathan O'Connell and John G. Houston -- $g14.$tMetal-enhanced fluorescence : application to high-throughput screening and drug discovery /$rKadir Aslan, Ignacy Gryczynski, Joanna Malicka, Joseph R. Lakowicz and Chris D. Geddes -- $g15.$tMethods for the design and analysis of replicate-experiment studies to establish assay reproducibility and the equivalence of two potency assays /$rBrian J. Eastwood, Amy K. Chesterfield, Mary C. Wolff and Christian C. Felder -- $g16.$tCoupled luminescent methods in drug discovery : 3-min assays for cytotoxicity and phosphatase activity /$rMichael J. Corey and Robert J. Kinders -- $g17.$tDesign and pharmaceutical applications of prodrugs /$rTomi Jarvinen, Jarkko Rautio, Mar Masson and Thorsteinn Loftsson -- $g18.$tGABA and glutamate receptor ligands and their therapeutic potential in CNS disorders /$rUlf Madsen, Hans Brauner-Osborne, Jeremy R. Greenwood, Tommy N. Johansen, Povl Krogsgaard-Larsen, Tommy Liljefors, Mogens Nielsen and Bente Frolund -- $g19.$tCardiac sarcolemmal ATP-sensitive potassium channel antagonists : novel ischemia-selective antiarrhythmic agents /$rGeorge E. Billman -- $g20.$tFactors influencing the efficacy of mediator-specific anti-inflammatory, glucocorticoid, and anticoagulant therapies for sepsis /$rPeter C. Minneci, Katherine J. Deans, Michael Haley, Xizhong Cui, Charles Natanson and Peter Q. Eichacker -- $g21.$tCombinatorial chemistry in the drug discovery process /$rNathan T. Ross, Brian R. McNaughton and Benjamin L. Miller -- $g22.$tHerbal medicines and animal models of gastrointestinal diseases /$rC. H. Cho and J. K. S. Ko -- $g23.$tEndocrine and metabolic agents /$rBrian L. Furman -- $g24.$tRespiratory viruses /$rPaul D. Olivo -- $g25.$tStrategies in the design of antiviral drugs /$rErik De Clercq and Piet Herdewijn -- $g26.$tProtein kinase inhibitors in drug discovery /$rKeykavous Parang and Gongqin Sun -- $g27.$tRNA-based therapies /$rSteve Pascolo -- $g28.$tNovel imaging agents for molecular MR imaging of cancer /$rDmitri Artemov and Zaver M. Bhujwalla -- $g29.$tTargets and approaches for cancer drug discovery /$rSusan L. Mooberry.
650 0 $aDrugs$xResearch$vHandbooks, manuals, etc.
650 0 $aDrug development$vHandbooks, manuals, etc.
650 0 $aDrugs$xDesign$vHandbooks, manuals, etc.
650 0 $aPharmaceutical chemistry$vHandbooks, manuals, etc.
650 12 $aPharmaceutical Preparations$vHandbooks.
650 12 $aDrug Design$vHandbooks.
650 12 $aChemistry, Pharmaceutical$vHandbooks.
700 1 $aGad, Shayne C.,$d1948-
856 41 $3Table of contents$uhttp://www.loc.gov/catdir/toc/ecip053/2004027077.html
852 00 $boff,hsl$hRM301.25$i.D784 2005